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Short Report:
Vertical Transmission of Kaposi’s Sarcoma-Associated Herpesvirus
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Before giving written consent to participate in the study, the
women were informed about the purpose of the study and counseled on HIV and KSHV. All women were enrolled before giving
birth and their newborns were enrolled immediately after delivery. In case of a multiple delivery, only the first sibling was enrolled into the study.

Little is presently known about the specific routes of transmission of
Kaposi’s sarcoma-associated herpesvirus (KSHV) or human herpesvirus-8 (HHV-8). To investigate whether this agent might be transmitted
vertically from mother to infant, we conducted a study on 89 KSHV
seropositive mothers and their newborn infants. Thirteen mothers
(14.6%) had KSHV DNA detected in their peripheral blood mononuclear cells (PBMC). Two of 89 samples drawn at birth from infants born
to KSHV seropositive mothers had KSHV DNA detectable within their
PBMC. These findings suggest that KSHV can be transmitted perinatally, but infrequently. Other routes of transmission such as horizontal transmission remain the most likely means of KSHV transmission.

Sample collection
Maternal and infant blood was collected by venipuncture into
acid citrate dextrose tubes and processed within 6 hours of being drawn. The blood samples from the mothers were drawn before delivery and those from the infants were drawn during their
first 24 hours of life.
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Kaposi’s sarcoma-associated herpesvirus is a recently isolated
gamma herpesvirus1 that has been found in all forms of Kaposi
Sarcoma (KS),2 and is now thought to play an important role in
the development of this tumor.3 Current knowledge about the
routes of transmission of KSHV is limited. Serological evidence
has suggested that there may be several routes of KSHV transmission, including sexual contact, as well as nonsexual contact via
saliva.4-7 In Africa, cross-sectional serological studies of children
in different age groups have shown that infection with KSHV
begins during early childhood and its frequency increases with
age.8-12 This suggests that non-sexual modes of transmission of
the virus may be occurring in Africa. The role of vertical transmission of this virus remains poorly understood. Some studies
have reported serological data disputing the occurrence of vertical transmission of KSHV13,14 whereas others have presented
contrasting serological data suggesting that vertical transmission
does occur.15,16 A case report of KS in a 6-day-old child17 strongly
suggests that KSHV may indeed be transmitted from a mother
to her infant in utero. In our study, we present evidence showing
that KSHV can be transmitted vertically from mother to infant.
Material and Methods
Patient recruitment
A subgroup of 89 KSHV seropositive women and their infants were selected from a cohort of over 2,000 mothers participating in a prospective study at the University Teaching Hospital (UTH) in Lusaka, Zambia. In this cohort, pregnant women in
the early stages of labor were recruited for the study at the time
of admission to the labor ward of the University Teaching Hospital (UTH), Lusaka, Zambia. Women who were in active labor
or who had more than 5cm cervical dilation were not recruited.

Isolation of peripheral blood mononuclear cells
The blood was centrifuged at 1,800 rpm for 10 minutes and the
plasma was collected then frozen at -20°C. The PBMC were isolated from whole blood using a ficol density gradient (Nycomed
Pharma AS, Oslo, Norway). The PBMC were then suspended in
fresh freezing medium (70% RMPI 1640, 20% fetal bovine serum,
10% DMSO) and stored at -80°C.
Screening for syphilis
Plasma was screened for Treponema pallidum antibodies using the rapid plasma reagin (RPR) testing kit (Arlington Scientific Inc, Springville, UT). All the RPR reactive samples were
then confirmed by Treponema pallidum hemagglutination using
the Serodia®-TP.PA kit (Fujirebio Inc., Tokyo, Japan).
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Immunofluorescence assay (IFA) for KSHV
Plasma was tested for KSHV antibodies by indirect IFA. BC-3
cells (kindly provided by Dr. Ethel Cesarman, Weill Medical College, Cornell University), a KSHV positive and Epstein-Barr virus (EBV) negative B-cell lymphoma cell line, were used for the
IFA. The IFA was performed using the procedure described by
Lennette et al.18 with minor modifications. Briefly, 5 x 105 cells/
ml were stimulated with tetra decanoyl phorbol acetate (TPA,
20 ng/ml, Sigma, St. Louis, MO) for 72 hours in culture medium
(90% RMPI 1640, 10% fetal calf serum, 100 U/ml penicillin G and
100 mg/ml streptomycin). Two different lab workers tested all
samples at 1:40 dilution. To exclude false positive results due to
background staining, all positive sera were retested with BJAB
cells (KSHV negative B lymphoma cell line). Only sera found
to be negative with uninfected cells were considered positive.
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Testing for HIV-1
Plasma was screened for HIV-1 antibodies using 2 rapid
assays, Capillus (Trinity Biotech Plc, Ireland) and Determine (Abbott Laboratories, Abbott Park, IL). The assays were
done according to the manufacturers’ instructions. IFA was
then used to confirm the HIV-1 result. The HIV IFA was performed as described above using a chronically HIV-1 infected T-cell line, HUT-78/ARV (given to us by Dr. Cecilia
Cheng-Mayer). Uninfected HUT-78 cells were used for background control. Plasma were considered HIV-1 positive if they
tested positive by at least one rapid test and confirmed by IFA.
Western blot analysis for antibodies to KSHV ORF65
An ORF65 bacterial clone, ORF65.2 (kindly provided by Dr.
T. Schulz), expressing the carboxylterminal half of ORF65 with
a 6xHis tag was used for Western blot analysis of sera. ORF65.2
protein was expressed then purified using immobilized metal
affinity chromatography according to the manufacturers’ procedure (Qiagen Ni-NTA Superflow, Qiagen, Chatsworth, CA).
Western blot was performed as follows. Ten microliters of each
test serum was blocked with 10 μl of normal E. coli bacterial
lysate for two hours at room temperature then diluted 1:50 in
blocking solution (20 mM Tris-HCl, pH 7.5; 500 mM NaCl; 0.1%
Tween 20; 5% skim milk; 5% normal goat serum). The membranes were incubated with the test serum for 1 hour at room
temperature then washed with TBST (20 mM Tris-HCl, pH 7.5;
500 mM NaCl; 0.1% Tween 20). The membrane was incubated
with alkaline phosphatase conjugated goat anti-human IgG (BioRad, Richmond, CA) and detection was performed using nitroblue tetrazolium and 5-bromo-4-chloro-3indolyphosphate
colorimetric substrate.19
Extraction of DNA from PBMC
Each cell pellet was incubated in 400 μl digestion buffer (100
mM NaCl, 10 mM Tris-HCl, pH 8.0, 25 mM EDTA, 0.5% SDS, 0.1
mg/ml Proteinase K) for 2 hours. Longer incubation times, up
to 15 hours, were used for larger cell pellets. The DNA was extracted by phenol/chloroform/isoamyl alcohol (25:24:1) extraction followed by ethanol precipitation.
PCR Analysis
PCR was performed using 2 sets of primers amplifying different genes of the KSHV genome. The KS-1 (5′-AGCCGAAAGATTCCACCAT-3′, genomic locus 47586-47605) and KS-2
(5′-TCCGTGTTGTCTACGTCCAG-3′, locus 47818-47799) primers, amplifying a 233 bp region of the ORF26 gene were used
for screening the DNA for KSHV sequences because they were
previously found to be most sensitive for detecting genomic
KSHV DNA.1 An extra pair of primers KS-4 (5′-CGAATCCAACGGATTTGACCTC-3′, locus 47611-47633) and KS-5
(5′-CCCATAAATGACACATTGGTGGTA-3′,
locus
4778547761) for the ORF26 gene was also used for the nested PCR of
the gene. Another set of primers, gBN-3 (5′-GCCACCCTGGGGACTGTCAT-3′, locus 8701-8720) and gBN-4 (5′-TTGGTGATGGCGGACTCTGTC-3′, locus 9083-9063) amplifying a 382 bp fragment of the N-terminal end of the glycoprotein B gene (gBN),
was used for screening in addition to the KS-1 and KS-2 primers.
All the primer sets were designed from the genomic sequence
U93872 (GenBank accession number U93872). The PCR reactions
were carried out in a PE 2400 thermal cycler (Perkin-Elmer, Oak
Brook, IL). Each reaction mixture (25 μl) contained 0.8 μM primers, 0.25 mM dNTP, 1.5 mM MgCl2, 20 mM Tris-HCl, pH 8.4, 50
mM KCl and 1 U Taq polymerase (GIBCO BRL, Gaithersburg,
MD). In every case, 300–400 ng of genomic DNA template was
used. Fifty nanograms of BC-3 DNA were used as the positive
control whereas 400 ng of BJAB DNA in one reaction tube and

2 μl deionized water in a second tube were used as the negative
controls. The cycling procedure for the KS-1, KS-2 primer pair
was 94°C for five minutes, then 35 cycles of 94°C for 30 seconds,
58°C for 30 seconds, 72°C for 30 seconds and one final extension
cycle of 7 minutes at 72°C. For the KS-4 and 5 and gBN primers,
the amplification conditions were similar except the annealing
temperature was at 53°C and 62°C, respectively.
Southern blot analysis
DNA was transferred onto a Zeta-Probe® nylon membrane
(Bio-Rad Laboratories, Hercules, CA) by vacuum transfer for
90 minutes and then cross-linked by ultra-violet irradiation.
Digoxigenin labeled PCR products from ORF26 and glycoprotein B were then used as probes, following a standard protocol
for hybridization and detection using nitroblue tetrazolium and
5-bromo-4-chloro-3-indolyphosphate colorimetric substrate.19
Cloning and sequencing of PCR products
The amplified product of the ORF26 nested reaction was
cloned into pGEM-T vector (Promega, Madison, WI) and the
cloned fragment was sequenced using ABI PRISM Big-dye terminator sequencing kit on an ABI 373S DNA sequencer (Applied
Biosystems; San Jose, CA).
Results
Medical history and clinical examination of the study participants
To document the occurrence of vertical transmission of KSHV
from seropositive mothers to their newborns, 89 women and
their infants in which DNA was available, were selected from the
group of HHV-8 seropositive women in an ongoing cohort study
in Zambia. The medical histories of the mothers are summarized
in Table I. Seven mothers had a positive history of tuberculosis.
One of the 89 women had a history of gonorrhea. Thirteen mothers had histories of ulcerative genital diseases. Clinical examination at the time of recruitment documented that ten mothers
had genital warts. Five mothers had non-genital skin ulcers. Two
women had Kaposi Sarcoma-like skin lesions but could not be
confirmed upon histological examination.
Serological analysis for KSHV antibodies in the mothers and their infants
Of the 89 mothers testing positive for KSHV by IFA, 72 (81%)
were also seropositive by ORF65 Western blot (Table II). Fiftyone women (57%) had a KSHV antibody titer greater than 1:40
(ranging from 1:80 to 1:1,280). With regards to HIV-1, 32 (36%)
of the 89 women in the cohort were HIV-1 seropositive with 8
of them (9%) also positive for syphilis (Table I). The infants born
to these 89 women were also characterized. The male:female ratio of the infants was 1:1. The mean birth weight was 2,852 g
(range 1,300–4,100 g). All the infants were born healthy and were
breast fed within the first 24 hours of their life. Most of the infants (74/89, 83.1%) were found to have passively acquired antiKSHV antibodies at birth by IFA (Table II). The acquisition of
maternal antibodies, however, did not correlate with high maternal antibody titers (data not shown).
PCR analysis of infant PBMC DNA for KSHV sequences
To determine if any of the infants born to these 89 KSHV seropositive women had acquired KSHV infection from their mothers, PCR was first performed on the infant PBMC DNA obtained
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at birth using the ORF26 primers. Of the 89 infant DNA samples
analyzed, KSHV DNA sequences were detected in two infants
after Southern blot analysis using a probe specific for the ORF26
gene. To confirm that KSHV DNA was indeed present in the infant PBMC, a second PCR assay was performed using primers
specific for the N-terminus of glycoprotein B. The same two infants were also positive using these primers.
PCR analysis of maternal PBMC DNA for KSHV sequences
The PBMC DNA of the 89 women was also analyzed for the
presence of KSHV DNA by PCR using primers specific for
ORF26. KSHV DNA was detected in 13 (14.6%) mothers (Table II). The PCR signal was quite weak and only detectable after
Southern blotting. Nine of the 13 KSHV DNA positive mothers
were HIV-1 seropositive (p < 0.001) indicating a possible correlation between HIV-1 infection and the presence of KSHV DNA
in this group of women. The number of specimens analyzed was
extremely small, however, and needs to be substantiated. Furthermore, we observed that five of the 13 KSHV DNA positive
mothers had a history of genital ulcers. The significance of such
an observation or whether there is a correlation between having KSHV DNA and a history of genital ulcers is not clear at this
point. The mothers of the two KSHV DNA positive infants were
also positive for KSHV DNA by PCR, but only one of the two
mothers was positive with both ORF26 and gBN primers. Both of
these mothers had KSHV antibody titers of 1:160, were HIV-1 seronegative and did not have any other conditions that may have
been risk factors for vertical transmission. The two mothers that
had unconfirmed KS-like lesions at the time of recruitment were
not found to be PCR positive for KSHV DNA in their PBMC.
KSHV DNA sequence analysis
The amplified ORF26 gene product from one of the infants was
cloned and sequenced. The cloned sequence is closely related to
recently published Zambian KSHV and other African sequences
with a conserved C at position 47738 of the ORF.17,18 This point
mutation is conserved amongst all Zambian KSHV ORF26 genes
sequenced so far and is distinct from BCBL KSHV sequences.20 The
infant sequence also had a unique point mutation (C to A) at position 47702 of the ORF26 sequence. This mutation was distinct from
the other known Zambian KSHV sequences (Figure 1). Several
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attempts were made to clone the KSHV PCR product from the
mother of the infant in which we had KSHV sequence information on. The maternal signal has consistently been weak and
only detectable by Southern blot. Subsequent cloning and analysis of the KSHV sequence from this patient was unsuccessful.
Discussion
Since the discovery of KSHV, the question of whether this agent
can be vertically transmitted has been intensely debated. Previous reports have presented serologic evidence disputing the possibility of vertical transmission of this virus.13,14 In these studies,
the clearance of maternal KSHV antibodies among infants followed longitudinally was demonstrated and KSHV DNA was
not detected in any of the infants tested. Plancoulaine et al.22 recently demonstrated in a French Guyana population of African
descent that KSHV transmission mainly occurs postnatally from
mother to child and from sibling to sibling. The low seroprevalence of KSHV among children less than 5 was cited as evidence
against vertical transmission being a major route of transmission. It has also previously been documented in Africa that primary infection with KSHV can occur during childhood.8-12 Kasolo et al.20 reported the finding of KSHV sequences in PBMC of
infants with febrile illnesses. The reported cases of KS in infants
less than 6 months of age,17,23 however, suggest the potential of
vertical transmission of KSHV. Our hypothesis that KSHV might
be transmittable from mother to infant perinatally was based
upon two previous observations: first that KS has become one of
the most common tumors among infants and children in Zambia and second, that KS is closely associated with KSHV infection. We have now identified two neonates who have tested positive for KSHV DNA at birth. This finding in these two infants
provides direct evidence of vertical transmission of KSHV. Interestingly, both infants were born to HIV-1 negative mothers. We
think that this is a chance finding. One would expect that HIV-1
positive mothers would be more likely to vertically transmit
KSHV to their babies because of higher viral copy numbers as a
result of their immunosuppression. We do not believe that these
results were due to contamination because KSHV DNA was detected in only two of the 89 infants that we tested. The fact that
PCR was done on the infants before DNA extraction and PCR on
the mothers PBMC DNA supports the claim that it is not a contamination from maternal sequences. Separate laboratories were
used for the extraction of DNA and PCR and the results were
confirmed by different researchers. Also, these same two infants
were positive with two different sets of non-nested PCR primers.
Furthermore, sequence analysis of the ORF26 gene from one of the
infants revealed that it is closely related to previously published
Zambian sequences of the same gene. Therefore contamination
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from maternal sequences or the laboratory BCBL strain is unlikely. The cloned portion of the ORF26 sequence, however, is
known to be relatively conserved and in our infant sequence, we
detected only two nucleotide changes with one of the changes
being conserved amongst Zambian KSHV isolates. We were
unable to clone other KSHV genes that show more variability
such as the ORF K1, or KSHV sequences from the mothers of the
two PCR-positive infants due to weak signals and insufficient
DNA. Although KSHV viral DNA in the PBMC of two infants
has been detected, it is difficult to determine whether infection
occurred in utero or intrapartum. Intrapartum or postnatal exposure as a result of breast feeding is unlikely because KSHV DNA
would not have been detected in the immediate postnatal period.
KSHV DNA has consistently been detected in KS tissues and
the viral copy numbers in these tissues are usually high.24 Other
tissues and body fluids in which KSHV DNA has been detected
include saliva, semen, skin, cervical secretions and PBMC.24-26
KSHV DNA is more easily detected in the bodily fluids of individuals with KS than in those without KS.24 This may be due
to lower copy numbers of KSHV DNA in individuals without
KS. In our study, we detected KSHV DNA in the PBMC of approximately 15% of the mothers. The KSHV copy numbers in the
PBMC DNA seem to be very low as we were only able to detect
the viral DNA by Southern blot analysis and not by direct gel examination of PCR-amplified products. In our hand, the limits of
detection of KSHV by the ORF26 and glycoprotein B PCR were
3 and 20 copies of viral DNA respectively. An increase in the
detection of KSHV DNA in HIV-1 positive mothers (9/13) compared to the HIV-1 negative mothers (4/13) was found to be sta-

tistically significant. This was based on a small number of PBMC
analyzed, however, and will need to be substantiated by testing
a larger number of samples. This finding nevertheless suggests
that HIV-1 may play a role in activating replication of KSHV
and thereby increasing the viral load of KSHV in the blood.
Several reports have documented that not all the children
born to KSHV infected mothers become KSHV seropositive at
birth.8-10,13 Our results here indicate that only 83% of the children
born to KSHV positive mothers acquired antibodies to KSHV.
Considering that only 57% of the mothers had a KSHV antibody
titer greater than 1:40 in our study, there seemed to be no correlation between the maternal KSHV antibody titer and the presence of KSHV antibodies in the infants.
In conclusion, we believe that our findings of two neonates
who at their birth have tested positive (with two different sets
of non-nested PCR primers) for KSHV DNA provide direct evidence of vertical transmission of KSHV. Although our findings
do suggest that the vertical transmission of KSHV may occur,
this is unlikely to be a major route of transmission of this virus to
children. In endemic areas, horizontal transmission remains the
most likely means by which infants become infected.
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